RxDoctor Payments Data

Tushar Acharya, MD

Cardiovascular Disease · Tucson, AZNPI 1922313774

Payments from drug & device makers

$2,899in general payments, 2019–2025

Across 36 payments — averaging $80.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Inari Medical, Inc.$137
  • Boehringer Ingelheim$116
  • Abiomed$107
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$61
  • Terumo Medical Corporation$35
  • plus $23 from 1 others

What the payments were for

  • Travel & lodging$1,79662%
  • Food & beverage$1,10238%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,899 in reported general payments places this provider in the 50th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$161,423
Medicare patients
1,516
Services billed
2,326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban281$368,255
EntrestoSacubitril/Valsartan57$106,744
XareltoRivaroxaban50$74,804
JardianceEmpagliflozin59$65,814
FarxigaDapagliflozin Propanediol39$50,543
Repatha SyringeEvolocumab19$25,377
Repatha SureclickEvolocumab16$24,558
RybelsusSemaglutide11$21,484
NexletolBempedoic Acid21$17,904
Metoprolol Succinate312$5,069
Rosuvastatin Calcium261$3,474
Flecainide Acetate71$3,186
Atorvastatin Calcium304$2,742
Losartan Potassium193$2,075
Spironolactone136$1,508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$116$65,81459 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →